Serum lipid level in Iranian patients with psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 6, 2007, Pages 802-805

  Farshchian, M ^a,b   Zamanian, A ^a   Monsef, A R ^c   Mahjub, H ^c  

^a Sina Hospital Hamedan   (Iran)

^b HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Blood glucose; Cardiovascular diseases; Dyslipidemia; Inflammation; Lipids; Psoriasis

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IRAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL; PSORIASIS; RISK ASSESSMENT; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IRAN; LIPIDS; MALE; PSORIASIS;

EID: 34250671559     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.02099.x     Document Type: Article

References (26)

1. Ortonne JP. Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol 1999; 140: 1-7.
2. Mallbris L, Akre O, Granath F et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-230.
3. Vahlquist C, Michaelsson G, Vessby B. Serum lipoproteins in middle-aged men with psoriasis. Acta Derm Venereol 1987; 67: 12-15.
4. Ena P, Madeddu P, Glorioso N et al. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiol 1985; 40: 199-205.
5. Vanizor Kural B, Orem A, Cimsit G et al. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta 2003; 328: 71-82.
6. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-986.
7. Behnam SM, Behnam SE, Koo JY. Smoking and psoriasis. Skinmed 2005; 4: 174-176.
8. Rocha-Pereira P, Santos-Silva A, Rebelo I et al. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004; 150: 917-928.
9. Chodorowska G, Wojnowska D, Juszkiewicz-Borowiec M. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol 2004; 18: 180-183.
10. Yeh ET. High-sensitivity C-reactive protein as a risk-assessment tool for cardiovascular disease. Clin Cardiol 2005; 28: 408-412.
11. Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: An overview of adverse effects. J Am Acad Dermatol 1999; 41: S7-S12.
12. Grossman RM, Delaney RJ, Brinton EA et al. Hypertriglyceridemia in patients with psoriasis treated with cyclosporine. J Am Acad Dermatol 1991; 25: 648-651.
13. Ballantyne C, Arroll B, Shepherd J. Lipids and CVD management: Towards a global consensus. Eur Heart J 2005; 26: 2224-2231.
14. Rocha-Pereira P, Santos-Silva A, Rebelo I et al. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001; 303: 33-39.
15. Uyanik BS, Ari Z, Onur E et al. Serum lipids and apolipoproteins in patients with psoriasis. Clin Chem Lab Med 2002; 40: 65-68.
16. Seckin D, Tokgozoglu L, Akkaya S. Are lipoprotein profile and lipoprotein (a) levels altered in men with psoriasis? J Am Acad Dermatol 1994; 31: 445-449.
17. Simonetti O, Ferretti G, Salvi A et al. Plasma lipid changes in psoriatic children. Dermatology 1992; 185: 96-100.
18. Seishima M, Seishima M, Mori S et al. Serum lipid and apolipoprotein levels in patients with psoriasis. Br J Dermatol 1994; 130: 738-742.
19. Fredriksson T, Pettersson U. Severe psoriasis -oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
20. Pietrzak A, Lecewicz-Torun B. Activity of serum lipase [EC 3.1.1.3]and the diversity of serum lipid profile in psoriasis. Med Sci Monit 2002; 8: CR9-CR13.
21. Reynoso-von Drateln C, Martinez-Abundis E, Balcazar-Munoz BR et al. Lipid profile, insulin secretion and insulin sensitivity in psoriasis. J Am Acad Dermatol 2003; 48: 882-885.
22. Cimsit G, Orem A, Deger O et al. The variation of serum lipoprotein (a) level with disease activity in psoriasis. Br J Dermatol 1998; 138: 917-919.
23. Aguilar Martinez A, Guerra Rodriguez P, Ambrojo Antunez P et al. Serum levels of apolipoproteins AI, AII and B in psoriasis. Dermatologica 1989; 179: 200-201.
24. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 1978; 99: 469-475.
25. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51: 563-569.
26. Mallbris L, Granath F, Hamsten A et al. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006; 54: 614-621.